Status:
UNKNOWN
Growth Hormone in EB
Lead Sponsor:
Cairo University
Conditions:
Epidermolysis Bullosa Dystrophica
Eligibility:
All Genders
1-12 years
Brief Summary
Growth is extremely affected in epidermolysis bullosa patients
Detailed Description
Studying the role of growth hormone and ILGF-1 in EB may pave the to new therapeutic modality that could improve the growth in those children and avoid the irreversible sequelae that affected subjects...
Eligibility Criteria
Inclusion
- \- Children with EB dystrophica
Exclusion
- Adults with the same disease
Key Trial Info
Start Date :
May 25 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 15 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05390073
Start Date
May 25 2022
End Date
June 15 2022
Last Update
May 25 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.